Abstract:
:Drug resistance is an expected consequence of antiviral therapy for chronic hepatitis B because of the high rate of hepatitis B virus (HBV) replication, the lack of proof-reading during reverse transcription of the pregenomic RNA and the low efficacy of available therapies in eliminating covalently closed circular HBV DNA. Mutations involving the YMDD motif of the catalytic domain of HBV reverse transcriptase have been reported in patients who have received lamivudine, emtricitabine and telbivudine. Drug-resistant mutations affecting other regions of HBV polymerase have also been reported, but at much lower rates in patients who have received adefovir dipivoxil or entecavir. Antiviral resistance is initially manifested as virological breakthrough infection. In most patients, this is followed by biochemical breakthrough and, in some patients, hepatitis flares and hepatic decompensation. Monitoring drug resistance may improve the management of patients with antiviral-resistant HBV and can guide the selection of salvage therapy. The optimal management of patients with antiviral-resistant HBV continues to evolve. The ideal approach is to prevent antiviral resistance through judicious use of antiviral therapy and the use of more potent antiviral agents, possibly in combination.
journal_name
Antivir Therjournal_title
Antiviral therapyauthors
Fung SK,Lok ASsubject
Has Abstractpub_date
2004-12-01 00:00:00pages
1013-26issue
6eissn
1359-6535issn
2040-2058journal_volume
9pub_type
杂志文章,评审abstract:BACKGROUND:A genome-wide association study revealed an association between variants of the inosine triphosphatase (ITPA) gene and ribavirin (RBV)-induced anaemia. The aim of this study was to replicate this finding in an independent Japanese cohort and to define a method to allow pretreatment prediction of anaemia in c...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1796
更新日期:2011-01-01 00:00:00
abstract:BACKGROUND:In haematopoietic stem cell transplant (HSCT) recipients, cytomegalovirus (CMV) infection contributes significantly to morbidity and mortality in both the early and late post-transplant period. Ganciclovir (GCV) is the treatment of choice for CMV, but requires intravenous administration, a fact that complica...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1858
更新日期:2011-01-01 00:00:00
abstract:BACKGROUND:Despite successful suppression of HIV-1 with HAART, some patients do not have robust immunological recovery. Chronic inflammation from persistent immune activation could contribute to this poor response, resulting in HIV-1 disease progression and the development of some non-HIV-1 comorbidities. METHODS:We c...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2350
更新日期:2012-01-01 00:00:00
abstract::Antiretroviral treatment with three nucleoside reverse transcriptase inhibitors (NRTIs) is widely used, but the combination of abacavir, didanosine and stavudine has never been investigated. We describe the surprising and consistent genotypic and phenotypic outcome in patients failing this combination. As part of a Da...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:
更新日期:2003-04-01 00:00:00
abstract:BACKGROUND:The tendency for haemorrhagic stroke in patients with chronic HCV infection has emerged recently but the finding may be confounded by comorbidities. Proving the causality between HCV infection and haemorrhagic stroke is mandatory. Our study was designed to investigate the incidence of intracranial haemorrhag...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP3172
更新日期:2018-01-01 00:00:00
abstract:OBJECTIVES:HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS:DNA pane...
journal_title:Antiviral therapy
pub_type: 杂志文章,多中心研究
doi:
更新日期:2007-01-01 00:00:00
abstract::The study was carried out to evaluate the therapeutic effects of zanamivir, a highly selective, potent and specific inhibitor of influenza A and B virus neuraminidases, in adult patients with acute influenza-like illness. Patients who presented within 36 h of the onset of influenza-like symptoms were randomly assigned...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:
更新日期:1999-01-01 00:00:00
abstract::The standard treatment of HCV infection with pegylated interferon-alpha2a or -alpha2b and ribavirin is effective in <50% of HCV genotype-1-infected patients. To improve this figure, it might be desirable to obtain optimal plasma concentrations of the drug by increasing the dose. Unfortunately, there is great interpati...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP1609
更新日期:2010-01-01 00:00:00
abstract:BACKGROUND:A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therap...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.3851/IMP3169
更新日期:2018-01-01 00:00:00
abstract::Neurological manifestations of HCV infection appear to be under-recognized in clinical practice despite the majority of HCV-infected patients experiencing symptoms such as fatigue, depression and cognitive dysfunction. There is also growing evidence for a link between HCV infection and an increased risk of Parkinson's...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP3245
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:The combination of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is the standard of care for hepatitis C virus (HCV) treatment in HIV-coinfected individuals. In 2007, abacavir (ABC)-based antiretroviral therapy was, for the first time, reported to be associated with early virological failure during HCV...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2008-01-01 00:00:00
abstract::Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data, but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of ...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP1730
更新日期:2011-01-01 00:00:00
abstract:BACKGROUND:Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy. Seven patients showed a delayed response to tenofovir. The present study was performed to evaluate the quasispecies variability and the in vitro drug susceptibility to approved antiviral drugs of ...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1940
更新日期:2012-01-01 00:00:00
abstract::HCV-related liver disease is an important contributor to morbidity and mortality in the HIV-infected population. Successful treatment of HIV-HCV-coinfected patients is followed by favourable clinical outcomes. While the combination of pegylated interferon and ribavirin remains the mainstay in the treatment of non-1 HC...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP2601
更新日期:2013-01-01 00:00:00
abstract::Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:2001-09-01 00:00:00
abstract:BACKGROUND/AIMS:We conducted a case-control study to investigate the efficacy of interferon-alpha (IFN-alpha) and ribavirin combination therapy for patients with chronic hepatitis C and B virus (HCV/HBV) coinfection and to elucidate the interaction of these two viruses. METHODS:Forty-two chronic HCV/HBV-coinfected pat...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2005-01-01 00:00:00
abstract::Combinations of two nucleoside analogue reverse transcriptase inhibitors plus a third agent represent the current standard for antiretroviral therapy. Stavudine is a nucleoside analogue that demonstrates in vitro activity against human immunodeficiency virus type 1 (HIV-1) and HIV-2 within an acceptable therapeutic in...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:1997-12-01 00:00:00
abstract:BACKGROUND:The influenza A virus accounts for serious annual viral upper respiratory tract infections. It is constantly able to modify its antigenic structure, thus evading host defence mechanisms. Moreover, currently available anti-influenza agents have a rather limited application, emphasizing the further need for ne...
journal_title:Antiviral therapy
pub_type: 杂志文章,收录出版
doi:10.3851/IMP3115
更新日期:2017-01-01 00:00:00
abstract::To our knowledge, there are no previously published cases of enteroviral infection complicated by pityriasis lichenoides et varioliformis acuta (PLEVA). A 30-year-old woman is reported with a severe form of PLEVA, preceded by hand, foot and mouth disease. Immunosuppressive treatment with cyclosporin A resulted in rapi...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP3012
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:CD4(+) T-cell count recovery after antiretroviral therapy (ART) initiation is associated with improved health outcomes. It is unknown how the CD4(+) T-cell counts of African HIV patients recover following ART initiation. METHODS:We examined CD4(+) T-cell count recovery in a large cohort of HIV-positive pati...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2670
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:The nucleotide analogue, tenofovir, has been shown to lower plasma atazanavir levels in pharmacokinetic trials, an interaction that may be partly reversed by the addition of ritonavir, whereas plasma tenofovir levels are themselves raised when the drug is combined with lopinavir/ritonavir. OBJECTIVE:To inve...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章
doi:
更新日期:2005-01-01 00:00:00
abstract:BACKGROUND:Single-drug class regimens with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are generally not recommended as initial therapy because they are inferior compared with therapy with two NRTIs plus efavirenz. However, triple-NRTI combinations can be useful in specific circumstances such as in t...
journal_title:Antiviral therapy
pub_type: 杂志文章,meta分析,评审
doi:10.3851/IMP2726
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:Lamivudine is widely used in patients with chronic hepatitis B virus (HBV) infection. In cirrhotic patients, long-term lamivudine therapy significantly reduced the risk of hepatocellular carcinoma (HCC). However, in a small but substantial portion of patients, HCC still developed despite lamivudine therapy. ...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2009-01-01 00:00:00
abstract::The use of nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of HIV infection is clearly linked to the development of subcutaneous fat atrophy. Until recently, however, in vitro studies of adipocytes have shown no or only modest and inconsistent effects of these agents on adipocyte biology. This is...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2006-01-01 00:00:00
abstract::With the recent approval of several drugs for the management of chronic hepatitis B, the proper diagnosis and classification of this disease is necessary to determine if therapy is needed and what the best treatment options are. The diagnosis of chronic hepatitis B relies on serological testing, and disease stage is f...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:2007-01-01 00:00:00
abstract::HIV-HBV-coinfected patients require optimal control of viral replication in order to prevent the development of severe comorbidities, such as liver cirrhosis and hepatocellular carcinoma. The genetic diversity of HBV is a poorly investigated factor of such viral replication in HIV-infected hosts. HBV genome diversity ...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP1495
更新日期:2010-01-01 00:00:00
abstract:BACKGROUND:Anaemia has been linked with mortality in HIV infection. The mechanism of anaemia in the era of contemporary antiretroviral therapy is not understood. The aim of this study was to describe the association between anaemia and markers of immune activation and inflammation in a cohort of HIV-infected adults on ...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.3851/IMP2940
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment. METHODS:A total of 243 patients from Cameroon receiving d4T or zidovudine (AZT) in combination with lamivudine and efavirenz or nevirapine for >6 months were clinically assesse...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1664
更新日期:2010-01-01 00:00:00
abstract:OBJECTIVE:The aim of the study was to analyse the response to highly active antiretroviral therapy (HAART) initiated at the time of primary HIV infection (PHI) in patients infected with a virus resistant to > or = 1 drug of their treatment compared with patients infected with a wild-type virus. METHODS:We analysed dat...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2007-01-01 00:00:00
abstract:BACKGROUND:Although thiazolidinediones have been shown to increase subcutaneous fat in congenital lipodystrophy, rosiglitazone did not show convincing results in HIV lipoatrophy. We assess a potential specific effect of pioglitazone in this setting. METHODS:One-hundred and thirty HIV-1-infected adults with self-report...
journal_title:Antiviral therapy
pub_type: 杂志文章,多中心研究,随机对照试验
doi:
更新日期:2008-01-01 00:00:00